General Surgery Department, Shanghai Jiao Tong University Sixth People's Hospital, China.
Acta Pharmacol Sin. 2011 Mar;32(3):354-60. doi: 10.1038/aps.2010.223.
To explore the role of Med19, a component of the Mediator complex that coactivates DNA-binding transcription factors, in the proliferation and tumorigenesis of human hepatocellular carcinoma cells.
The human hepatocellular carcinoma cell lines HepG2 and Hep3B were infected with lentiviral vectors encoding interfering RNA (RNAi) targeting the Med19 gene. To further confirm the inhibitory effects of RNAi vectors on Med19 gene expression, quantitative real-time RT-PCR and Western blotting assays were used. The proliferation of HepG2 and Hep3B cells after transduction with the Med19-RNAi-Lentivirus vector was evaluated by MTT conversion, BrdU incorporation, colony formation, and cell-cycle assays in vitro. In addition, the ability of the Med19-RNAi-Lentivirus vector-infected Hep3B cells to form tumors after inoculation into nude mice was determined.
Recombinant lentiviral vectors expressing small interfering RNA (siRNA) against Med19 were constructed and were found to efficiently downregulate Med19 mRNA and protein levels in HepG2 and Hep3B cells. Furthermore, the inhibition of Med19 by RNAi dramatically reduced hepatocellular carcinoma cell proliferation, induced cell-cycle arrest in the G(0)/G(1) phase, and suppressed tumor formation.
These results provide new evidence of an important role for Med19 in the development of hepatocellular carcinomas, suggesting that lentivirus-mediated RNAi to target Med19 is a potential tool for inhibiting cancer cell proliferation and tumorigenesis.
探讨 Mediator 复合物的组成部分 Med19 在人肝癌细胞增殖和致瘤中的作用。
用人肝癌细胞系 HepG2 和 Hep3B 感染靶向 Med19 基因的慢病毒载体。为进一步证实 RNAi 载体对 Med19 基因表达的抑制作用,采用实时定量 RT-PCR 和 Western blot 检测。用 MTT 转化、BrdU 掺入、集落形成和细胞周期检测体外转染 Med19-RNAi-Lentivirus 载体后 HepG2 和 Hep3B 细胞的增殖。此外,还测定了 Med19-RNAi-Lentivirus 载体感染的 Hep3B 细胞接种裸鼠后形成肿瘤的能力。
构建了表达针对 Med19 的小干扰 RNA (siRNA)的重组慢病毒载体,并发现其能有效下调 HepG2 和 Hep3B 细胞中的 Med19 mRNA 和蛋白水平。此外,RNAi 对 Med19 的抑制作用显著降低肝癌细胞的增殖,诱导细胞周期停滞在 G(0)/G(1)期,并抑制肿瘤形成。
这些结果为 Med19 在肝癌发生发展中的重要作用提供了新的证据,提示慢病毒介导的 RNAi 靶向 Med19 可能是抑制癌细胞增殖和肿瘤发生的一种潜在工具。